Board summary
Key figures
37,770
Registered population
59.7% aged 18–64
21.4%
Aged 65+
ICB 14.9% · England 17.9%
18.5%
In IMD quintile 1
ICB 40.7% · England 21.0%
~6,833
Core20 residents (est.)
Resident basis; registered basis ~6,514 · see page 3
7,088
Hypertension register
+9.37% in 3 yrs · England +5.60%
447
SMI register
14.3% of Rochdale (LAD)'s
1,021
COPD register
Reviews +10.66% in 3 yrs
Forecast to 2030
8,686
Hypertension patients, 2030
+1,598 on today
69.6%
QRISK ≥20% on statins, 2030
+2.39pp over 3 yrs
5.5%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Learning disability prevalence fell over three years.
QOF learning disability prevalence (216 patients) changed -8.5% over 2023 to 2025 (England +5.4%, Rochdale (LAD) -15.8%), which may reflect coding differences requiring audit.
Three-year changes trail England across 13 measures.
Across 25 measures, 13 trail England's 2023 to 2025 change, including QRISK ≥ 20% lipid therapy (+3.8% vs England +6.2% and Rochdale (LAD) +4.9%).
Cervical screening coverage exceeds all comparators.
Cervical screening at ages 25-49 reaches 78.8% (Rochdale (LAD) 68.8%, NHS Greater Manchester Integrated Care Board 65.9%, England 66.8%), rising +2.7% (England -1.0%).
Population, age and ethnicity
Patients aged 65+ comprise 21.4% of registrations, exceeding borough and national rates
Across six constituent practices and 37,770 registered patients, 21.4% (8,076 patients) are aged 65+, above Rochdale (14.7%), NHS Greater Manchester Integrated Care Board (14.9%) and England (17.9%). Those aged 0-17 comprise 18.9% (7,133), below Rochdale (23.5%), the ICB (21.8%) and England (19.6%); 59.7% (22,561) are aged 18-64 (Rochdale 61.8%, ICB 63.3%, England 62.7%). Recorded Gypsy or Irish Traveller and Roma groups are 0.0% (Rochdale 0.1%, ICB 0.1%, England 0.1% and 0.2%). Projected list growth to 2030 is 1.1% (Rochdale 1.4%, ICB 1.6%, England 2.3%). Observation periods are unstated and projection methodology is unverified.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Rochdale (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Rochdale LA) | 2,300 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.1% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 61.8% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Rochdale LA) | 1,088 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Rochdale LA) | 19.0 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is below borough levels but spans 10.1 pp across practices
PENNINES PCN has an average IMD decile of 4.4 and a Core20 registered share of 18.5%, below Rochdale (48.0%), NHS Greater Manchester Integrated Care Board (40.7%) and England (21.0%). The weighted practice share is 17.3%, an unverified 1.23 pp discrepancy. Across practices, Core20 shares span a 10.1 pp range. Milnrow Village Practice records 12.1%, while Littleborough Group Practice records 22.2%. Targeting balances concentration and volume: Littleborough Group Practice has 1,890 estimated Core20 patients, whereas Stonefield Street Surgery has 1,317 estimated Core20 patients despite a 15.0% share.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
447
SMI register
1.19% recorded prevalence
216
Learning disability register
0.57% recorded prevalence
18
Care homes, 446 beds
In the PCN catchment
9.7%
Provide unpaid care
Rochdale (LAD), Census 2021
Inclusion-health registers record 447 severe mental illness patients (1.2% vs England 1.0%) and 216 with learning disabilities (0.6% vs England 0.6%), with 18 catchment care homes (446 beds). Borough benchmarks show 9.7% unpaid carers and 2 rough sleepers in 2025; these are local authority figures, not PCN headcounts.
Severe mental illness: physical health checks
SMI prevalence is 1.2% (England 1.0%). Recorded checks show 85.8% for blood pressure and 83.1% for BMI, where three-year progress (+2.0 pp) trailed England (+5.1 pp). Slower recording growth may leave cardiovascular risks unaddressed across the 447 patients.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,088
Hypertension register
+9.37%
Register growth, 3 yrs
Rochdale (LAD) +6.17% · England +5.60%
+0.57pp
BP control, under 80
≤140/90 · +1.18pp aged 80+
+1,598
More patients by 2030
Forecast 8,686 (22.48%)
Hypertension case-finding and control
Hypertension recorded prevalence is 18.8% (7,088 patients), above Rochdale (15.6%), NHS Greater Manchester Integrated Care Board (14.4%) and England (15.2%), with the register expanding +9.4% over 2023 to 2025 (England +5.6%). Recent blood pressure recording reaches 90.3% (England 90.0%) and treatment to target is 71.2% (England 70.3%). However, three-year progress in blood pressure control for patients under 80 rose +0.8%, trailing Rochdale (+3.1%) and England (+3.2%), with current control at 67.7% (England 67.8%). Slower control gains could reflect titration delays, though unverified locally. With blood pressure control progress trailing national gains despite high recording, prioritising medication titration and home blood pressure monitoring could improve outcomes across this large registered caseload.
Lipids and statins
For patients with QRISK ≥ 20%, 64.5% receive lipid-lowering therapy, above England (63.6%) but behind Rochdale (68.3%), while diabetes statin coverage is 72.6% (England 73.2%, Rochdale 76.6%). Lower therapy rates than borough peers indicate an opportunity to audit high-risk QRISK and diabetes registers to expand primary cardiovascular prevention.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 58,580 | £2.30 | £1.94 | £1.86 | £134,734 |
| Cardiovascular (all), 2025 | 80,738 | £4.57 | £3.15 | £3.33 | £368,973 |
In 2026, the PCN prescribed 58,580 lipid-modifying items at £2.30 per item, compared with Rochdale (£2.08), NHS Greater Manchester Integrated Care Board (£1.94), and England (£1.86), spending £25,775 more than at England's unit cost. Higher unit costs than comparators highlight an opportunity for a formulary review to optimise statin choices without compromising clinical control.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+9.89%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.39%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.8% (2,766 patients; England 6.6%) and COPD is 2.7% (1,021 patients; England 1.9%). Annual reviews reached 68.5% in asthma (England 65.7%) and 80.5% in COPD (England 76.4%), leaving about 870 asthma patients unreviewed. Asthma prescribing in ages 5–19 is 1,979 items per 1,000 (England 1,488), while second-hand smoke recording for ages 6–19 (78.0%, 255 patients) trails Rochdale (81.6%). This combination could reflect unreviewed maintenance or environmental exposure, though not locally verified.
Cancer register and children's immunisation
Cancer prevalence is 4.6% (1,733 patients; England 3.8%). In childhood immunisation (Q1 2025/26), 6-in-1 coverage at 12 months is 95.8% (calculated England 91.0%), exceeding the 95.0% target. At age 5, 4-in-1 pre-school booster coverage is 90.2%, below the 95.0% target by 4.8 pp, while MMR dose 1 (96.7%) exceeds dose 2 (94.6%) by 2.1 pp. Lower booster uptake may leave children under-protected before school entry.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, 55.6% of cancers with a known stage in NHS Greater Manchester ICB (6,491 of 11,679) were diagnosed at stage 1 or 2, above England (55.3%) but below the 75.0% national ambition by 19.4 pp, leaving a gap of about 2,270 extra early-stage diagnoses. Known stage was recorded for 70.8% of registrations (11,679 of 16,492); these figures describe the ICB rather than PCN performance. Pennines PCN records 1,733 cancer patients (4.6% prevalence vs England 3.8%) and screening coverage of 78.8% in cervical and 78.0% in breast.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), Northern Care Alliance NHS Foundation Trust achieved 78.6% on the 62-day cancer standard, below the 85.0% standard by 6.4 pp, trailing Calderdale and Huddersfield NHS Foundation Trust (87.7%) but ahead of Tameside and Glossop Integrated Care NHS Foundation Trust (76.8%), NHS Greater Manchester Integrated Care Board (75.7%) and England (71.2%). Its 28-day faster diagnosis reached 75.2% (standard 75.0%), and 31-day treatment reached 94.5% (standard 96.0%). Six-week diagnostic waits were 5.1% for MRI and 4.1% for CT. These acute trust metrics describe provider performance, not PCN performance.
| Pathways within standard (%) | Northern Care Alliance | Tameside and Glossop Integrated Care | Calderdale and Huddersfield | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 75.20 | 82.48 | 77.98 | 79.53 | 79.32 |
| 31-day treatment (96%) | 94.54 | 96.25 | 97.89 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 78.65 | 76.77 | 87.66 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Northern Care Alliance | Tameside and Glossop Integrated Care | Calderdale and Huddersfield | England |
|---|---|---|---|---|
| MRI | 5.09 | 0.00 | 6.29 | 21.40 |
| CT | 4.10 | 0.18 | 0.59 | 9.92 |
| Echocardiography | 31.48 | 0.00 | 44.12 | 28.48 |
| Colonoscopy | 40.04 | 1.51 | 0.56 | 30.83 |
| Gastroscopy | 36.48 | 5.45 | 0.29 | 29.02 |
| All 15 DM01 tests | 15.71 | 0.80 | 11.48 | 23.14 |
| Community services activity | Rochdale residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 60,250 | 573,310 |
| Referrals | 9,455 | 94,470 |
| Patients with a contact | 19,345 | 183,535 |
Community services (residents of Rochdale), Jun 2026 (provisional). In June 2026 (provisional), Community Services Dataset records show 24,650 of 60,250 community contacts for Rochdale residents were with adults aged 65 and over, representing 40.9% of total activity. These borough-level figures describe local authority residents' activity rather than PCN performance.
Practice variation and patient experience
Good practice experience exceeds England despite a 22.7 percentage point phone access spread
In 2025/26, practice clinical QOF achievement reached 95.3% to 100.0% against England's 97.1%. However, vaccination and immunisation domain achievement spans 49.0 pp, from 41.9% at Littleborough Group Practice to 90.9% at The Village Medical Ctr. against England's 55.2%. Personalised care adjustments in this domain ranged from 0.7% to 4.6%.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Milnrow Village | 110 | 12.1 | 92.0% | 81.6% | 95.4% |
| Village Medical | 104 | 19.4 | 69.4% | 62.4% | 94.0% |
| Trinity | 123 | 19.7 | 88.2% | 76.0% | 92.6% |
| Stonefield Street | 94 | 15.0 | 72.1% | 80.8% | 90.4% |
| Pennine Surgery | 110 | 17.4 | 91.2% | 71.8% | 90.3% |
| Littleborough | 119 | 22.2 | 72.9% | 83.0% | 87.3% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Across 25 compared measures, 13 trail England's three-year change despite solid current achievement
Across 25 compared measures, 13 trail England's three-year change from 2023 to 2025. Slower trajectories are led by learning disability prevalence, which fell 8.5% (England +5.4%, Rochdale (LAD) -15.8%), and heart failure reviews, which rose +3.9% (England +8.7%), despite current review coverage reaching 81.3% (England 78.5%). Conversely, three-year gains showed PCN strength in respiratory care, where COPD reviews rose +10.7% (England +2.8%) and asthma reviews grew +9.9% (England +4.4%). Trailing review growth alongside high current coverage suggests progress may be plateauing, making focused clinical recall worthwhile.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Learning disability register
Heart failure reviews
BMI record (SMI)
QRISK statin treatment
BP control, under 80
COPD reviews
Asthma reviews
Cervical screening
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Rochdale (LAD) | Asset | PCN | Rochdale (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 18 (446 beds) | n/a | Schools (catchment) | 41 | n/a |
| Children's centres | 2 | 17 | Places of worship | 27 | 116 |
| Libraries | 5 | 12 | Primary schools (LA maintained) | 7 | 38 |
| Primary academies | 7 | 26 | Special schools | n/a | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review and prescribing recall
Across 2,766 asthma patients (7.8% vs England 6.6%), 68.5% had a review in the last 12 months (Rochdale (LAD) 66.2%, England 65.7%), leaving 871 (about 870) unreviewed. For discussion, the PCN could run a single-template asthma recall combining inhaler checks and second-hand smoke recording across high-share and high-volume Core20 practices. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Learning disability register validation and recall
The learning disability register holds 216 patients (0.6% vs Rochdale (LAD) 0.7%, England 0.6%), falling 8.5% over 2023 to 2025 (England +5.4%), giving a +6 to +32 modelled gap. For discussion, practices could audit diagnostic codes against historical records and social-care lists where sharing exists, alongside accessible annual review invitations. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Option 3
Hypertension titration and lipid therapy review
Across 7,088 hypertension patients (18.8% vs England 15.2%), under-80 BP control is 67.7% (+0.8% over 2023 to 2025 vs +3.2%); 2026 lipid-modifying items cost £2.30 (England £1.86). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Learning disability register audit (p2) | Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Two-track Core20 outreach targeting (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Annual SMI physical health review (p4) | Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension titration protocol (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall outreach (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening uptake outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Review appointment booking pathways (p9) | GPPS last request led to a booked appointment | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma review and prescribing recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Learning disability register validation and recall (p12) | Learning disability register · Learning disability: QOF prevalence · Registered population | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Option 3 · Hypertension titration and lipid therapy review (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
